ABVC BioPharma (NASDAQ:ABVC) Announces Quarterly Earnings Results

ABVC BioPharma (NASDAQ:ABVC) posted its quarterly earnings data on Tuesday. The company reported ($0.11) earnings per share (EPS) for the quarter, FiscalAI reports.

ABVC BioPharma Price Performance

ABVC opened at $1.45 on Thursday. ABVC BioPharma has a 12-month low of $0.61 and a 12-month high of $5.48. The business has a 50 day moving average of $1.89 and a 200-day moving average of $2.47. The stock has a market cap of $36.86 million, a price-to-earnings ratio of -7.25 and a beta of 0.28.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ABVC BioPharma in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, ABVC BioPharma presently has an average rating of “Sell”.

Institutional Investors Weigh In On ABVC BioPharma

A number of institutional investors have recently modified their holdings of the business. Geode Capital Management LLC grew its stake in ABVC BioPharma by 5.8% during the second quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock worth $246,000 after buying an additional 6,017 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of ABVC BioPharma during the 3rd quarter worth approximately $48,000. Finally, Millennium Management LLC bought a new position in ABVC BioPharma in the third quarter valued at approximately $60,000. Institutional investors own 11.38% of the company’s stock.

ABVC BioPharma Company Profile

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.